Report cover image

Global Recombinant Coagulation Factor ? for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 193 Pages
SKU # APRC20355956

Description

Summary

According to APO Research, The global Recombinant Coagulation Factor Ⅷ for Injection market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Recombinant Coagulation Factor Ⅷ for Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Recombinant Coagulation Factor Ⅷ for Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Recombinant Coagulation Factor Ⅷ for Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Recombinant Coagulation Factor Ⅷ for Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Recombinant Coagulation Factor Ⅷ for Injection include GC Pharma, Novo Nordisk A/S, SinoCell Tech, Baxter, Bayer, Hualan Biological, Pfizer, Shanghai Raas Corp and Shanghai Xinxing Medicine, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Recombinant Coagulation Factor Ⅷ for Injection, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Recombinant Coagulation Factor Ⅷ for Injection, also provides the sales of main regions and countries. Of the upcoming market potential for Recombinant Coagulation Factor Ⅷ for Injection, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Recombinant Coagulation Factor Ⅷ for Injection sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Recombinant Coagulation Factor Ⅷ for Injection market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Recombinant Coagulation Factor Ⅷ for Injection sales, projected growth trends, production technology, application and end-user industry.

Recombinant Coagulation Factor Ⅷ for Injection Segment by Company

GC Pharma
Novo Nordisk A/S
SinoCell Tech
Baxter
Bayer
Hualan Biological
Pfizer
Shanghai Raas Corp
Shanghai Xinxing Medicine
Shandong Taibang Biological Products
Recombinant Coagulation Factor Ⅷ for Injection Segment by Type

250 IU/Bottle
500 IU/Bottle
1000 IU/Bottle
2000 IU/Bottle
Recombinant Coagulation Factor Ⅷ for Injection Segment by Application

Hospital
Clinic
Others
Recombinant Coagulation Factor Ⅷ for Injection Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Coagulation Factor Ⅷ for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Coagulation Factor Ⅷ for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Coagulation Factor Ⅷ for Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Recombinant Coagulation Factor Ⅷ for Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Coagulation Factor Ⅷ for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Recombinant Coagulation Factor Ⅷ for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Recombinant Coagulation Factor Ⅷ for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Table of Contents

193 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Recombinant Coagulation Factor Ⅷ for Injection Market Size, 2020 VS 2024 VS 2031
1.3 Global Recombinant Coagulation Factor Ⅷ for Injection Market Size Estimates and Forecasts (2020-2031)
1.4 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Estimates and Forecasts (2020-2031)
1.5 Global Recombinant Coagulation Factor Ⅷ for Injection Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Recombinant Coagulation Factor Ⅷ for Injection Market Dynamics
2.1 Recombinant Coagulation Factor Ⅷ for Injection Industry Trends
2.2 Recombinant Coagulation Factor Ⅷ for Injection Industry Drivers
2.3 Recombinant Coagulation Factor Ⅷ for Injection Industry Opportunities and Challenges
2.4 Recombinant Coagulation Factor Ⅷ for Injection Industry Restraints
3 Recombinant Coagulation Factor Ⅷ for Injection Market by Manufacturers
3.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Manufacturers (2020-2025)
3.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Manufacturers (2020-2025)
3.3 Global Recombinant Coagulation Factor Ⅷ for Injection Average Sales Price by Manufacturers (2020-2025)
3.4 Global Recombinant Coagulation Factor Ⅷ for Injection Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Recombinant Coagulation Factor Ⅷ for Injection Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Recombinant Coagulation Factor Ⅷ for Injection Manufacturers, Product Type & Application
3.7 Global Recombinant Coagulation Factor Ⅷ for Injection Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Recombinant Coagulation Factor Ⅷ for Injection Market CR5 and HHI
3.8.2 Global Top 5 and 10 Recombinant Coagulation Factor Ⅷ for Injection Players Market Share by Revenue in 2024
3.8.3 2024 Recombinant Coagulation Factor Ⅷ for Injection Tier 1, Tier 2, and Tier 3
4 Recombinant Coagulation Factor Ⅷ for Injection Market by Type
4.1 Recombinant Coagulation Factor Ⅷ for Injection Type Introduction
4.1.1 250 IU/Bottle
4.1.2 500 IU/Bottle
4.1.3 1000 IU/Bottle
4.1.4 2000 IU/Bottle
4.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type
4.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2020-2031)
4.2.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Type (2020-2031)
4.3 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type
4.3.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2020-2031)
4.3.3 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Type (2020-2031)
5 Recombinant Coagulation Factor Ⅷ for Injection Market by Application
5.1 Recombinant Coagulation Factor Ⅷ for Injection Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.1.3 Others
5.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application
5.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2020-2031)
5.2.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Application (2020-2031)
5.3 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application
5.3.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2020-2031)
5.3.3 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Application (2020-2031)
6 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region
6.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region (2020-2031)
6.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region (2020-2025)
6.2.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Recombinant Coagulation Factor Ⅷ for Injection Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Recombinant Coagulation Factor Ⅷ for Injection Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Recombinant Coagulation Factor Ⅷ for Injection Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region
7.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region
7.1.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region (2020-2025)
7.1.3 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region (2026-2031)
7.1.4 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Recombinant Coagulation Factor Ⅷ for Injection Revenue (2020-2031)
7.2.2 North America Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue (2020-2031)
7.3.2 Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Recombinant Coagulation Factor Ⅷ for Injection Revenue (2020-2031)
7.4.2 Asia-Pacific Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 GC Pharma
8.1.1 GC Pharma Comapny Information
8.1.2 GC Pharma Business Overview
8.1.3 GC Pharma Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 GC Pharma Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
8.1.5 GC Pharma Recent Developments
8.2 Novo Nordisk A/S
8.2.1 Novo Nordisk A/S Comapny Information
8.2.2 Novo Nordisk A/S Business Overview
8.2.3 Novo Nordisk A/S Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Novo Nordisk A/S Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
8.2.5 Novo Nordisk A/S Recent Developments
8.3 SinoCell Tech
8.3.1 SinoCell Tech Comapny Information
8.3.2 SinoCell Tech Business Overview
8.3.3 SinoCell Tech Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 SinoCell Tech Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
8.3.5 SinoCell Tech Recent Developments
8.4 Baxter
8.4.1 Baxter Comapny Information
8.4.2 Baxter Business Overview
8.4.3 Baxter Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Baxter Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
8.4.5 Baxter Recent Developments
8.5 Bayer
8.5.1 Bayer Comapny Information
8.5.2 Bayer Business Overview
8.5.3 Bayer Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Bayer Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
8.5.5 Bayer Recent Developments
8.6 Hualan Biological
8.6.1 Hualan Biological Comapny Information
8.6.2 Hualan Biological Business Overview
8.6.3 Hualan Biological Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Hualan Biological Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
8.6.5 Hualan Biological Recent Developments
8.7 Pfizer
8.7.1 Pfizer Comapny Information
8.7.2 Pfizer Business Overview
8.7.3 Pfizer Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Pfizer Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
8.7.5 Pfizer Recent Developments
8.8 Shanghai Raas Corp
8.8.1 Shanghai Raas Corp Comapny Information
8.8.2 Shanghai Raas Corp Business Overview
8.8.3 Shanghai Raas Corp Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Shanghai Raas Corp Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
8.8.5 Shanghai Raas Corp Recent Developments
8.9 Shanghai Xinxing Medicine
8.9.1 Shanghai Xinxing Medicine Comapny Information
8.9.2 Shanghai Xinxing Medicine Business Overview
8.9.3 Shanghai Xinxing Medicine Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Shanghai Xinxing Medicine Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
8.9.5 Shanghai Xinxing Medicine Recent Developments
8.10 Shandong Taibang Biological Products
8.10.1 Shandong Taibang Biological Products Comapny Information
8.10.2 Shandong Taibang Biological Products Business Overview
8.10.3 Shandong Taibang Biological Products Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Shandong Taibang Biological Products Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
8.10.5 Shandong Taibang Biological Products Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Recombinant Coagulation Factor Ⅷ for Injection Value Chain Analysis
9.1.1 Recombinant Coagulation Factor Ⅷ for Injection Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Recombinant Coagulation Factor Ⅷ for Injection Production Mode & Process
9.2 Recombinant Coagulation Factor Ⅷ for Injection Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Recombinant Coagulation Factor Ⅷ for Injection Distributors
9.2.3 Recombinant Coagulation Factor Ⅷ for Injection Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.